Sg3 Management, LLC Incyte Corp Call Options Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $2.11 Million - $2.58 Million	-30,000 Closed	0 $0
Q3 2022 May 15, 2023	BUY	$66.18 - $82.86 $1.99 Million - $2.49 Million	30,000 New	30,000 $2 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $1.99 Million - $2.49 Million	30,000 New	30,000 $2 Million
Q4 2021 Feb 15, 2022	SELL	$63.34 - $74.11 $2.85 Million - $3.33 Million	-45,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $2.58 Million - $3.15 Million	37,500 Added 500.0%	45,000 $3.1 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $599,025 - $656,475	7,500 New	7,500 $631,000
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $1.21 Million - $1.47 Million	-15,000 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $1.28 Million - $1.65 Million	15,000 New	15,000 $1.35 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.